Skip to content

VR as preparation for care as usual for patients with a panic disorder or social phobia.

VR as preparation for care as usual for patients with a panic disorder or social phobia. - VR in patients (12-18 or 18+) with panic disorder or sociale phobia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48032
Enrollment
24
Registered
2020-06-18
Start date
2020-12-07
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Social phobia and panic disorder

Interventions

Four VR sessions in which participants will be exposed to public traffic, a supermarket, a shopping district and a party in the garden.

Sponsors

ProPersona (Nijmegen)
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: - DSM-5 diagnosis: panic disorder or social phobia, measured with the MINI KID (adolescents) or MINI (adults) - Age between 12 and 18 (adolescents) of 18+

Exclusion criteria

Exclusion criteria: - patients are diagnosed with a severe depressive disorder for which they need immediate treatment (measured with the MINI or MINI KID) - patients are diagnosed with a psychosis for which they need immediate treatment (measured with the MINI or MINI KID) - Mental retardation (IQ below 70) - Substance abuse or dependence or alcohol abuse or dependence - Psychofarmacology is changed in the last 8 weeks

Design outcomes

Primary

MeasureTime frame
- willingness to take part in exposure in vivo Measured with the Friedman-test (non-parametric). When they differ significantly we will use post-hoc analyses (Wilcoxon Signed Rank Test with a Bonferroni correction).

Secondary

MeasureTime frame
Anxiety Expectancy, activation of anxiety, approachability and course of symptoms (anxiety/depression) will be visual reproduced as descriptive statistics.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)